IPM Take
Alzheimer’s research has spent years arguing over amyloid. Tau never left the room.
Biogen’s diranersen data give the tau field a reason to breathe again. The company reports reductions in tau biomarkers and favourable clinical trends at one dose. That is worth attention. But the story is not clean enough for celebration.
A biomarker can move. A dose can look promising. A subgroup can look better than expected. None of that is the same as proving that people remember longer, function better or stay independent for more time.
Tau is back in the argument. Certainty is not.
Executive Summary
Biogen presented Phase 2 CELIA data for diranersen, BIIB080, an investigational antisense oligonucleotide targeting tau in early Alzheimer’s disease, at the Alzheimer’s Association International Conference.
The company reported that the 60 mg dose showed the strongest clinical response, including reported slowing of decline versus placebo on ADAS-Cog13, MMSE and CDR-SB measures at 18 months. Biogen also reported reductions in cerebrospinal-fluid total tau and phosphorylated tau, alongside reductions in tau PET signal.
The findings remain early. Biogen previously reported that CELIA did not meet its primary endpoint assessing dose response. Higher doses were not associated with greater slowing of clinical decline, creating an important interpretation challenge.
Biogen plans to advance diranersen into Phase 3. That next study will need to show whether tau lowering translates into patient-relevant clinical benefit.
Why it matters
- Patients / advocates: Alzheimer’s families need more than another biological story. They need evidence that a treatment changes memory, function and daily life.
- Clinicians: Tau-directed therapy is scientifically compelling, but the dose-response uncertainty means the findings cannot be read as a clean efficacy result.
- Researchers / academia: The data strengthen the case for tau as a therapeutic target while reminding the field that biomarker movement does not automatically settle clinical value.
- Regulators: Any future approval argument will need a robust link between tau reduction and meaningful clinical outcomes.
Alzheimer’s research has a bad habit of turning mechanisms into movements.
A target becomes fashionable. A biomarker becomes persuasive. A trial result is presented as if the biology has already spoken clearly enough. Then patients and families are left waiting while the evidence catches up, or fails to.
Diranersen deserves a more disciplined reading.
The tau hypothesis is not trivial. Tau pathology is closely linked to neurodegeneration and cognitive decline in Alzheimer’s disease. A therapy that can reduce tau biology in humans and show a directional clinical signal deserves serious development.
But the CELIA data are not a final answer.
The strongest signal appears at one dose. The study missed its primary dose-response endpoint. Higher doses did not produce a clearer clinical effect. Those facts do not kill the programme, but they do stop the story from becoming simple.
This is exactly the kind of evidence moment where Alzheimer’s policy needs maturity.
The field should not dismiss a promising signal because it is complicated. It should also not treat complexity as a detail to be managed by optimistic language. The reason to proceed to Phase 3 is not that the question has been answered. It is that the question has become important enough to ask properly.
If diranersen works, the next trial must show it in terms patients can recognise: memory, daily function, time, independence and caregiver burden.
Until then, tau is a serious lead. It is not yet a treatment promise.
